Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention

Vaccines

Lucia H. Lee¹  Xin-Xing Gu² 

[1] Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA;National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA; E-Mail:

关键词: Streptococcus pneumoniae;    vaccine;    epidemiology;    serotype;    pneumococcal protein;   

DOI  :  10.3390/vaccines2010112

来源: mdpi

【 摘 要 】

Seven-valent pneumococcal conjugate vaccine (PCV7) introduction and routine pediatric use has substantially reduced the burden of Streptococcus pneumoniae disease worldwide. However, a significant amount of disease burden, due to serotypes not contained in PCV7, still exists globally. A newly recognized serotype, 6C, was until recently, identified and reported as serotype 6A. This review summarizes the serotype epidemiology of pneumococcal disease pre- and post-introduction of PCV7, available post-marketing surveillance data following the introduction of higher valency pneumococcal vaccines (PCV10, PCV13) and future prospects for the development of new pneumococcal vaccines.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.